Dissociative Disorders in Obesity (Dissobe)
NCT05081778 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 240
Last updated 2021-10-18
Summary
THe aim of this study is to determine the frequency of dissociative tendencies in the obese population treated at the CELIOBE (Liberal Center for Obesity Support) at Hôpital Privé La Louvière among patients consulting for the first time and looking for a medical or surgical course. The DES scale of Carlson and Putman will be used.
Conditions
- Obesity
- Dissociative Disorder
Interventions
- BEHAVIORAL
-
Obese patient following a medical course
Questionnaires for the assessment of dissociative disorders in obese patients : DES scale of Carlson and Putman, SDQ-20 of Nijenhuis, comorbidities, Dutch Eating Behaviour Questionnaire (DEBQ), questionnaire of Rosenberg
Sponsors & Collaborators
-
European Clinical Trial Experts Network
collaborator OTHER -
Ramsay Générale de Santé
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-05-05
- Primary Completion
- 2019-07-05
- Completion
- 2019-12-05
Countries
- France
Study Locations
More Related Trials
-
A Study of Olanzapine in Participants With Bipolar Disorder.
NCT07263191 ·Status: RECRUITING
-
Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00090012 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed
NCT00618748 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Clozapine for the Treatment of Psychosis in Patients With Idiopathic Parkinson's Disease
NCT00004826 ·Status: COMPLETED ·Phase: NA
-
Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)
NCT00303602 ·Status: COMPLETED ·Phase: PHASE4
-
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044187 ·Status: COMPLETED ·Phase: PHASE4
-
Naltrexone for Antipsychotic-Induced Weight Gain
NCT01866098 ·Status: COMPLETED ·Phase: NA
-
Metabolic Profile and Anthropometric Changes in Schizophrenia
NCT00534183 ·Status: COMPLETED ·Phase: NA
-
A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)
NCT00780585 ·Status: COMPLETED
-
Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia
NCT02332798 ·Status: COMPLETED ·Phase: PHASE1
-
Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode
NCT00191997 ·Status: COMPLETED ·Phase: PHASE4
-
Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia
NCT00345033 ·Status: COMPLETED ·Phase: PHASE4
-
A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia
NCT01518894 ·Status: COMPLETED ·Phase: PHASE1
-
Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia
NCT00793780 ·Status: COMPLETED ·Phase: NA
-
Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine
NCT00401973 ·Status: COMPLETED ·Phase: PHASE3
-
Multicenter, Open-label, Safety and Tolerability Study
NCT01649557 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Amantadine for Weight Stabilization During Olanzapine Treatment
NCT00287352 ·Status: COMPLETED ·Phase: PHASE1
-
A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia
NCT00645099 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Situations Leading to the Prescription of Neuroleptics by General Practitioner in the Elderly. Practice Survey
NCT03116100 ·Status: COMPLETED
-
Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine
NCT00312598 ·Status: COMPLETED
-
The Effect of a Weight Management Program During Treatment With Olanzapine
NCT00169702 ·Status: COMPLETED ·Phase: NA
-
Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fed Condition
NCT01503450 ·Status: COMPLETED ·Phase: PHASE1
-
Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study
NCT01962402 ·Status: UNKNOWN ·Phase: PHASE4
-
Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine
NCT01491490 ·Status: TERMINATED ·Phase: PHASE2
-
A Safety and Tolerability Study of Paliperidone Palmitate Injected in the Shoulder or the Buttock Muscle in Patients With Schizophrenia
NCT00119756 ·Status: COMPLETED ·Phase: PHASE3